Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer

Kinoshita, Rumiko; Mitamura, Takashi; Kato, Fumi; Hattori, Takahiro; Higaki, Hajime; Takahashi, Shuhei; Fujita, Yoshihiro; Otsuka, Manami; Koizumi, Fuki; Uchinami, Yusuke; Mori, Takashi; Nishioka, Kentaro; Hashimoto, Takayuki; Ito, Yoichi M.; Watari, Hidemichi; Aoyama, Hidefumi

Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer

Kinoshita, Rumiko; Mitamura, Takashi; Kato, Fumi et al.

Journal of Radiation Research, 2023, 64(2), 463-470

Permalink : https://hdl.handle.net/2115/88794

このアイテムのアクセス数:374件（2026-03-04 23:07 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1093/jrr/rrac086			2

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/88794
タイトル	Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer
著者	Kinoshita, Rumiko ; Mitamura, Takashi ; Kato, Fumi ; Hattori, Takahiro ; Higaki, Hajime ; Takahashi, Shuhei ; Fujita, Yoshihiro ; Otsuka, Manami ; Koizumi, Fuki ; Uchinami, Yusuke ; Mori, Takashi ; Nishioka, Kentaro ; Hashimoto, Takayuki ; Ito, Yoichi M. ; Watari, Hidemichi ; Aoyama, Hidefumi
e-Rad_Researcher 70507582 著者名 Kinoshita, Rumiko
e-Rad_Researcher 90625641 著者名 Mitamura, Takashi
著者名 Kato, Fumi
著者名 Hattori, Takahiro
著者名 Higaki, Hajime
著者名 Takahashi, Shuhei
著者名 Fujita, Yoshihiro
著者名 Otsuka, Manami
著者名 Koizumi, Fuki
著者名 Uchinami, Yusuke
著者名 Mori, Takashi
著者名 Nishioka, Kentaro
著者名 Hashimoto, Takayuki
著者名 Ito, Yoichi M.
著者名 Watari, Hidemichi
e-Rad_Researcher 80360915 著者名 Aoyama, Hidefumi
言語	英語
キーワード	cervical cancer
	definitive radiotherapy
	human papilloma virus (HPV) genotype
	prognosis
発行日	2023-03
出版者	Oxford University Press
収録物名	Journal of Radiation Research
巻(号)	64(2)
ページ	463-470
抄録	Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, alpha-7 HPV and alpha-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPV alpha-7, HPV alpha-9 and negatives. Of the 46 patients, 10 were positive for HPV alpha-7, 21 positive for HPV alpha-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPV alpha-7, HPV alpha-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPV alpha-7 showed statistically significant poorer PC than the HPV alpha-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	0449-3060
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1093/jrr/rrac086